10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2018 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 19, 2019) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Revenue | $ 24,555,700 | 22,871,300 | 21,222,100 |
| Costs, expenses, and other: | |||
| Cost of sales | 6,430,000 | 6,150,800 | 5,710,100 |
| Research and development | 5,307,100 | 5,357,300 | 5,310,300 |
| Marketing, selling, and administrative | 6,631,800 | 6,680,100 | 6,528,000 |
| Acquired in-process research and development (Notes 3) | 1,983,900 | 1,112,600 | 30,000 |
| Asset impairment, restructuring, and other special charges (Note 5) | 482,000 | 1,673,600 | 382,500 |
| Othernet, (income) expense (Note 17) | (74,800) | (300,500) | (112,800) |
| Cost of sales, operating expenses, and other-net | 20,760,000 | 20,673,900 | 17,848,100 |
| Income before income taxes | 3,795,700 | 2,197,400 | 3,374,000 |
| Income taxes (Note 13) | 563,700 | 2,401,500 | 636,400 |
| Net income (loss) | 3,232,000 | (204,100) | 2,737,600 |
| Earnings (loss) per share: | |||
| Basic (usd per share) | 3.14 | (0.19) | 2.59 |
| Diluted (usd per share) | 3.13 | (0.19) | 2.58 |
| Shares used in calculation of earnings (loss) per share: | |||
| Basic (shares) | 1,027,721 | 1,052,023 | 1,058,324 |
| Diluted (shares) | 1,033,667 | 1,052,023 | 1,061,825 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2018 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 19, 2019) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Net income (loss) | $ 3,232,000 | (204,100) | 2,737,600 |
| Other comprehensive income (loss): | |||
| Change in foreign currency translation gains (losses) | (440,700) | 501,900 | (436,400) |
| Change in net unrealized gains (losses) on securities | (8,800) | (181,300) | 303,000 |
| Change in defined benefit pension and retiree health benefit plans (Note 14) | 569,400 | (576,600) | (512,800) |
| Change in effective portion of cash flow hedges | (6,000) | 27,800 | 11,700 |
| Other comprehensive income (loss) before income taxes | 113,900 | (228,200) | (634,500) |
| Benefit (provision) for income taxes related to other comprehensive income (loss) items | (30,300) | 402,700 | (10,600) |
| Net other comprehensive income (loss) | 83,600 [1] | 174,500 | (645,100) |
| Comprehensive income (loss) | 3,315,600 | (29,600) | 2,092,500 |
| [1] Other comprehensive income in 2018 consists of $72.6 million of other comprehensive income attributable to controlling interest and $11.0 million of other comprehensive income attributable to noncontrolling interest. Other comprehensive income in 2017 consists of $199.0 million of other comprehensive income attributable to controlling interest and $24.5 million of other comprehensive loss attributable to noncontrolling interest. Other comprehensive loss in 2016 consists of $693.3 million of other comprehens | |||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2018 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 19, 2019) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Net Cash Provided by Operating Activities [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income (loss) | $ 3,232,000 | (204,100) | 2,737,600 |
| Adjustments to Reconcile Net Income (Loss) to Cash Flows from Operating Activities: | |||
| Depreciation and amortization | 1,609,000 | 1,567,300 | 1,496,600 |
| Change in deferred income taxes | 326,800 | (787,900) | 439,500 |
| Stock-based compensation expense | 279,500 | 281,300 | 255,300 |
| Acquired in-process research and development | 1,983,900 | 1,112,600 | 30,000 |
| Other non-cash operating activities, net | 472,000 | 441,500 | 376,100 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (996,700) | (357,000) | (709,400) |
| Inventories(increase) decrease | 7,800 | (253,900) | (328,200) |
| Other assets(increase) decrease | (980,000) | (590,100) | (265,500) |
| Income taxes payableincrease (decrease) | (125,300) | 3,489,600 | (304,800) |
| Accounts payable and other liabilitiesincrease (decrease) | (284,500) | 916,300 | 1,123,800 |
| Net Cash Provided by Operating Activities | 5,524,500 | 5,615,600 | 4,851,000 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,210,600) | (1,076,800) | (1,037,000) |
| Proceeds from disposals of property and equipment | 3,600 | 40,700 | 73,400 |
| Proceeds from sales and maturities of short-term investments | 2,552,500 | 4,852,500 | 1,642,000 |
| Purchases of short-term investments | (112,200) | (3,389,700) | (1,327,400) |
| Proceeds from sales of noncurrent investments | 3,509,500 | 2,586,000 | 2,086,000 |
| Purchases of noncurrent investments | (837,900) | (4,611,600) | (4,346,000) |
| Purchases of in-process research and development | (1,807,600) | (1,086,800) | (55,000) |
| Cash paid for acquisitions, net of cash acquired (Note 3) | 0 | (882,100) | (45,000) |
| Other investing activities, net | (191,300) | (215,800) | (130,100) |
| Net Cash Provided by (Used for) Investing Activities | 1,906,000 | (3,783,600) | (3,139,100) |
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,311,800) | (2,192,100) | (2,158,500) |
| Net change in short-term borrowings | (2,197,900) | 1,397,500 | 1,293,200 |
| Proceeds from issuance of long-term debt | 2,477,700 | 2,232,000 | 1,206,600 |
| Repayments of long-term debt | (1,009,100) | (630,600) | (200) |
| Purchases of common stock | (4,150,700) | (299,800) | (600,100) |
| Net proceeds from Elanco initial public offering (Note 3) | 1,659,700 | 0 | 0 |
| Other financing activities, net | (372,800) | (364,400) | (300,800) |
| Net Cash Provided by (Used for) Financing Activities | (5,904,900) | 142,600 | (559,800) |
| Effect of exchange rate changes on cash and cash equivalents | (63,600) | (20,500) | (236,400) |
| Net increase in cash and cash equivalents | 1,462,000 | 1,954,100 | 915,700 |
| Cash and cash equivalents at beginning of year | 6,536,200 | 4,582,100 | |
| Cash and Cash Equivalents at End of Year | 7,998,200 | 6,536,200 | 4,582,100 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ELI LILLY & CO | ||
Ticker: LLY Fiscal Year: 2018 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 19, 2019) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2018 | Dec 31, 2017 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents (Note 7) | $ 7,998,200 | 6,536,200 |
| Short-term investments (Note 7) | 88,200 | 1,497,900 |
| Accounts receivable, net of allowances of $32.5 (2018) and $38.7 (2017) | 5,246,500 | 4,546,300 |
| Other receivables | 958,400 | 715,900 |
| Inventories (Note 6) | 4,111,800 | 4,458,300 |
| Prepaid expenses and other | 2,146,500 | 1,447,500 |
| Total current assets | 20,549,600 | 19,202,100 |
| Other Assets | ||
| Investments (Note 7) | 2,020,700 | 5,678,800 |
| Goodwill (Note 8) | 4,347,500 | 4,370,100 |
| Other intangibles, net (Note 8) | 3,521,000 | 4,029,200 |
| Deferred tax assets (Note 13) | 2,657,700 | 1,166,400 |
| Sundry | 1,892,400 | 1,707,900 |
| Total other assets | 14,439,300 | 16,952,400 |
| Property and equipment, net (Note 9) | 8,919,500 | 8,826,500 |
| Total assets | 43,908,400 | 44,981,000 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt (Note 10) | 1,131,200 | 3,706,600 |
| Accounts payable | 1,412,300 | 1,410,700 |
| Employee compensation | 1,054,500 | 997,900 |
| Sales rebates and discounts | 5,021,900 | 4,465,100 |
| Dividends payable | 650,800 | 590,600 |
| Income taxes payable (Note 13) | 404,000 | 532,900 |
| Other current liabilities | 2,213,400 | 2,832,100 |
| Total current liabilities | 11,888,100 | 14,535,900 |
| Other Liabilities | ||
| Long-term debt (Note 10) | 11,639,700 | 9,940,500 |
| Accrued retirement benefits (Note 14) | 2,911,300 | 3,513,900 |
| Long-term income taxes payable (Note 13) | 3,724,600 | 3,776,500 |
| Other noncurrent liabilities | 2,835,600 | 1,546,300 |
| Total other liabilities | 21,111,200 | 18,777,200 |
| Commitments and Contingencies (Note 15) | ||
| Eli Lilly and Company Shareholders' Equity (Notes 11 and 12) | ||
| Common stockno par value Authorized shares: 3,200,000 Issued shares: 1,057,639 (2018) and 1,100,672 (2017) | 661,000 | 687,900 |
| Additional paid-in capital | 6,583,600 | 5,817,800 |
| Retained earnings | 11,395,900 | 13,894,100 |
| Employee benefit trust | (3,013,200) | (3,013,200) |
| Accumulated other comprehensive loss (Note 16) | (5,729,200) | (5,718,600) |
| Cost of common stock in treasury | (69,400) | (75,800) |
| Total Eli Lilly and Company shareholders' equity | 9,828,700 | 11,592,200 |
| Noncontrolling interests | 1,080,400 | 75,700 |
| Total equity | 10,909,100 | 11,667,900 |
| Total liabilities and equity | 43,908,400 | 44,981,000 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |